Advertisement

Topics

Flex Pharma to cut two trials, reduce headcount and explore merger options

09:52 EDT 14 Jun 2018 | in-PharmaTechnologis

Oral tolerability concerns have prompted the US biotech to close Ph II clinical trial investigations of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).

Original Article: Flex Pharma to cut two trials, reduce headcount and explore merger options

NEXT ARTICLE

More From BioPortfolio on "Flex Pharma to cut two trials, reduce headcount and explore merger options"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...